4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
ImmunityBio, Inc. (IBRX) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 684 employees. Its market capitalization is roughly $9 billion. In the fiscal year ended 2025-12-31, IBRX reported $113M in revenue and ($351M) in net income.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.
Interactive charts & full statements → Open the IBRX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $113M | $15M | $1M | $0M | — |
| Gross Profit | $112M | $15M | $1M | $0M | — |
| Operating Income (EBIT) | ($256M) | ($344M) | ($361M) | ($351M) | — |
| Net Income | ($351M) | ($414M) | ($583M) | ($417M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $44M | $38M | $32M | $26M | $16M | — |
| Gross Profit | $44M | $38M | $32M | $26M | $16M | — |
| Operating Income (EBIT) | ($70M) | ($65M) | ($56M) | ($71M) | ($64M) | — |
| Net Income | ($633M) | ($62M) | ($67M) | ($93M) | ($130M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Dividends Paid | — | — | — | — | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $502M | $383M | $504M | $362M | — |
| Total Liabilities | $1.0B | $871M | $1.1B | $812M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IBRX viewer.
About TickerBase · Data methodology & sources